TABLE 1.
Type of infection | Chimpanzee | Route of inoculationc | ALT
|
Viremia
|
||
---|---|---|---|---|---|---|
Maximum activity (U/liter) | Duration (wks) of elevationa | Maximum titerb (RNA copies/ml) | Duration (wks) (>400 copies/mla) | |||
Primary HCV 1a inoculation | Ch4X0186 | i.v. | 160 | >8 | 2 × 105 | 8 + 1d |
Ch1552 | i.h. | 249 | 10 + 1 | 1 × 107 | 15 + 1 | |
Ch1605 | i.v. | 176 | 10 + 1 | 1 × 106 | 11 + 1 | |
Rechallenge with homologous HCV 1a | Ch4X0186 | i.v. | 53 | 2 + 1 | <4 × 102 | 0 |
Ch1552 | i.v. | 31 | 1 + 1 | 4 × 103 | 1 + 1 | |
Ch1605 | i.v. | 70 | 3 + 1 | 5 × 104 | 1 + 1 | |
Rechallenge with heterologous HCV 1b | Ch4X0186 | i.v. | 86 | 1 + 1 | <4 × 102 | 0 |
Serum samples were tested at weekly intervals; the durations of ALT elevation and viremia are therefore indicated with 1-week variance.
Quantitative real-time RT-PCR (sensitivity, 400 RNA copies/ml).
i.v., intravenous HCV infection; i.h., intrahepatic transfection with in vitro-transcribed HCV RNA.
Robert Lanford, personal communication.